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ABSTRACT
Objectives: The objective of the paper is the suitability assessment of screening for Trisomy 18 and 13 on the basis of NT 
measurement, FHR, double test and assessment of Nasal Bone.
Material and methods: The study was performed in 6,661 singleton pregnancies. In each fetus NT, FHR, DV-PIV were 
examined. Double test from maternal blood was examined. These ultrasound and biochemical factors were in combined 
screening investigated. Additional ultrasound marker — Nasal Bone was and its impact on Trisomies 18 and 13 screening 
was examined.
Results: Two groups of patients were compared — with chromosomal normal and chromosomal abnormalities — Trisomy 
18 and 13. Detection Rate of Trisomies 18 and 13 at the risk cutoff 1/300 using combined screening was 84.1% and FPR 
was 7.1%. Detection Rates of examined chromosomal abnormalities using screening with additional marker — NB was 
93.2% and False Positive Rate — 5.6%.
Conclusions: It should be noted that the qualitative analysis of the assessment of NB in the first trimester significantly 
influences the improvement of screening values focusing on Trisomy 18 and 13 detection. In summary, our research in-
dicates a more effective type of Trisomy 13 and 18 screening using NT, double test, maternal age, CRL and FHR as well as 
nasal bone presence and absence.
Key words: combined test Trisomy 18 Trisomy 13; first trimester nuchal translucency thickness; Nasal Bone; Serum free 
β-hCG; Pregnancy-associated plasma protein A
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INTRODUCTION
The main objective of screening tests in the first trimester 
of gestation is to assess the risk of chromosomal (most often 
Trisomy 21, 13 and 18) based on ultrasound examination 
(nuchal translucency [NT] assessment, fetal heart rate [FHR]). 
What is more, the assessment of the double test (the level of 
the free β- subunit of human chorionic gonadotropin and 
pregnancy plasma protein type A-PAPP-A are assessed) as 
well as maternal age [1, 2] were also taken into consideration.
By means of this methodology, the detection rate (DR) 
for Trisomy 21 is 87% at FPR (False-positive Results) 5.3%, 
whereas 90% at FPR 3.1% [1, 3]. The detectability of Trisomy 
18 and 13 is 97% and 94%, respectively, at FPR 3.1% [1, 3]. 
Additional markers are used in screening for Trisomy 21: 
assessment of the presence of nasal bone, which increases 
detection of Trisomy 21 by about 5% in the case of FPR from 
4.8 to 3.4% [4].
The objective of this retrospective study was
The work is a retrospective study assessing the use of 
an additional ultrasound marker in the prenatal examination 
of the first trimester (11+0–13+6 weeks of gestation), which 
is the nasal bone, in the analysis of chromosomal aberration 
screening: Trisomy 18 and 13.
MATERIAL AND METHODS
We had 6,844 pregnant women included in the study 
with single pregnancies who underwent prenatal screening 
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of 1st trimester assessing the risk of occurrence of Trisomy 
18 and 13 in the years 2014–2019. It should be stressed that 
the fetuses with other syndromes (Trisomy 21 — 84 , Turner 
Syndrome — 14, Tetraploidy — 5, Unbalanced transloca-
tions — 6 cases respectively) and structural defects with 
normal karyotype, such as: heart defects — Hypoplastic 
Left Heart Syndrome — 13 , Atrioventricular Septal De-
fects — 7, Tetrallogy of Fallot — 4 and Transposition of the 
Great Arteries — 2 cases were excluded from the research. 
Other structural fetal defects excluding fetuses from the 
study were: Fetal Hydrops — 15, Spina bifida — 11, Hydro-
cephalus — 7, Palate or upper lips cleft — 7, Omphalocele 
— 4 and Gastroschisis — 4 cases. The study was performed 
in pregnancies scanned in the Department of Obstetrics and 
Gynecology in Ruda Śląska, Outpatient ‘Sonomedico’ Żory 
and in Outpatient Clinic ‘GENOM’ in Ruda Śląska. The risk 
was calculated using the Fetalmedicine Foundation (FMF) 
certified program The First Trimester Screening Program or 
Astraia (Astraia Software G.m.b.H., Munich, Germany). These 
pregnant women were retrospectively divided into two 
groups: patients with a low risk of chromosomal defects, 
who gave birth to healthy children were included in the 
control group (6617 pregnant), whereas, the study group 
included patients (44 pregnant women) whose fetuses were 
diagnosed with Trisomy 18 and 13.
All patients who were at increased risk of developing Tri-
somy 18 or 13 made decisions to undergo invasive diagnos-
tics. Edwards Syndrome (Trisomy 18) and Patau Syndrome 
(Trisomy 13) were found after amniocentesis and cytoge-
netic tests. Amniotic fluid obtained during amniocentesis 
after genetic consultation and obtaining written consent of 
the patient for amniocentesis were used for these tests. In-
vasive diagnostics were performed in pregnant women 
with increased risk of Trisomy 18 and 13 in age-related risk.
Ultrasound examination during the first trimester was 
performed between 11+0 and 13+6 weeks of gestation ac-
cording to the recommendations of FMF and the Ultrasonog-
raphy Section of the Polish Gynaecological Society [3]. During 
the ultrasound examination, the following parameters were 
evaluated: crown-rump length (CRL), fetal heart rate (FHR), 
nuchal translucency (NT) and, additionally, nasal bone (NB), 
(nasal bone — its presence or absence). A Double Marker Test 
was performed, and the mother’s age at the time of examina-
tion was noted. The first trimester ultrasound was performed 
by specialists in obstetrics and gynaecology certified by the 
Fetal Medicine Foundation and the Ultrasound Section of the 
Polish Society of Gynaecologists and Obstetricians. The ultra-
sound examination was performed with Volusion 730 Expert, 
Volusion E6, E8 and E10 (GE Healthcare). Each patient was 
serum examinated level to a double test on the day of ultra-
sound examination: assessment of the β-hCG free subunit 
level (human β- chorionic gonadotropin free subunit) and 
PAPP-A level (plasma protein A during pregnancy) in venous 
blood. Levels of the tested substances were individually cal-
culated for each patient on MoM (multiples of the median). 
Biochemical tests were carried out using the Kryptor method 
of the Brahms company (Kryptor, Brahms Diagnostica GmbH, 
Berlin, Germany) and Delfia Express-Perkin Elmer USA.
The results were analysed using the PQStat statistical 
package ver. 1.4.2.324. The results of the analyses were pre-
sented in the tables of descriptive statistics and two-split 
tables and on the charts. The results of the β-hCG MoM, 
PAPP-A MoM scales depending on the group (testing and 
control) were compared using the Mann-Whitney U test. The 
presence and absence of the nasal bone in healthy fetuses 
and sick fetuses were analysed by determining detection 
rates and the number of false-positive results along with con-
fidence intervals and using ROC analyzes. The risk of Trisomy 
18 and 13 divided into > 1/300 > 1/200.1 > 100 > 1/50 and 
with coincident consideration of the presence or absence of 
the nasal bone of healthy fetuses and afflicted fetuses was 
analysed by estimating detection rates and the number of 
false positive results with confidence intervals. The risk of 
Trisomy of 18 and 13 was also analysed using ROC curve. 
The test probability on the level of p < 0.05 was considered 
statistically important and noticeable.
RESULTS
The control group included 6,617 pregnant women 
aged between 14 to 46 years of age (mean age of preg-
nant women was 31 years), ultrasound examination was 
performed between 11+0 and 14th weeks of gestation (on 
mean 12+3 weeks of gestation). The CRL size of the fetuses 
ranged from 45 to 84 mm (mean CRL of fetuses was 63.7mm). 
The mean nuchal translucency in the control group was 
1.8 mm (min. 0.8 mm, max. 13.1 mm). In 200 (3.02%) of 
fetuses from the control group, the nasal bone was not 
present (Tab. 1, 4).
Fourty-four pregnant women aged between of 20–
41 were included in the study group (the mean age of 
pregnant women was 29). Ultrasound examination was 
performed between 11+0 and 13+6 weeks of gestation (on 
mean 12+2 weeks of gestation). CRL size of fetuses ranged 
from 47 mm to 81.1 mm (mean size of fetuses was 58.8 mm) 
The mean nuchal translucency in the study group was 
5.1 mm (min 1.7 mm, max 8.3 mm). In the examined group 
nasal bone was found in 14 fetuses — in 8 fetuses with Ed-
wards syndrome and in 6 fetuses with Patau syndrome. In 
30 (68.18%) fetuses with Trisomy 18 and 13 the nasal bone 
was not found during ultrasound examination (Tab. 2, 4).
The differences in NT thickness, MoM β-hCG and MoM 
PAPP-A as well as the percentage of presence or absence of 
nasal bone in the control and study group was statistically 
significant (Tab. 3).
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As a result of further analysis, patients were divided into 
4 groups depending on the level of risk of Trisomy 18 and 13: 
the first group with a risk above 1:300 and the second with 
a risk above 1:200, the third with a risk above 1:100 and the 
fourth group with a risk above 1:50 occurrence of Trisomy 
18 and 13. DR and FPR as well as positive and negative ratio 
(LH + and LH-) were assessed in each group. Each group 
was divided into two subgroups, in one of them the risk of 
Trisomy 18 and 13 was assessed basing on the patient age, 
NT, FHR, and double PAPP-A test. In the second group, the 
same fetuses had an estimated risk based on the patient’s 
age, NT, FHR, double test and nasal bone assessment. The 
highest DR was in the risk group > 1:300 and was 84% for 
fetuses in which the nasal bone was left beyond the scope 
of the study and 93% for fetuses in which the presence 
or absence of the nasal bone was assessed. In this group, 
we obtained a decrease in FPR from 7.1% (group without 
nasal bone assessment) to 5.6% (in the group with nasal 
bone assessment). The lowest DR was found in the group 
at risk > 1:50 i.e. 56% (screening without nasal bone assess-
ment) and 75% (screening with nasal bone assessment) with 
a similar FPR of 1.1% (Tab. 5).
Table 1. Control group
mean SD min. max. median 25th percentile (lower quartile) 75th percentile (upper quartile)
age [years] 31 5.54 14 46 31 27 36
CRL [mm] 63.7 8.47 45 84 63.4 57.8 69.5
NT [mm] 1.8 0.56 0.8 13.1 1.8 1.5 2
FHR [/min] 160 6.25 131 206 160 156 164
β-hCG MoM 1.238 0.814 0.08 9.181 1.023 0.702 1.538
PAPP-A MoM 1.076 0.576 0.052 6 0.958 0.671 1.354
CRL — crown-rump length; FHR — fetal heart rate; MoM — multiples of the median; NT — nuchal translucency; SD — standard deviation
Table 2. Study group
mean SD min. max. median 25th percentile (lower quartile) 75th percentile (upper quartile)
age [years] 29 6.08 20 41 28 25 33
CRL [mm] 58.8 8.9 47 81.1 56.5 51.3 63.6
NT [mm] 5.1 1.66 1.7 8.3 5.7 3.9 6.4
FHR (/min) 159 11.7 135 179 158 150 170
β-hCG MoM 1.238 0.814 0.08 9.181 1.023 0.702 1.538
PAPP-A MoM 0.533 0.663 0.1 2.995 0.295 0.242 0.48
CRL — crown-rump length; FHR — fetal heart rate; MoM — multiples of the median; NT — nuchal translucency; SD — standard deviation
Table 3. Both groups selected parameters comparison
Healthy 
fetuses
Trisomy 18  
and 13 fetuses p value
NT [median] 1.8 mm 5.7 mm p < 0.001
β-hCG
MoM [median] 1.023 0.46 p < 0.001
PAPP-A MoM [median] 0.958 0.295 p < 0.001
Percentage of nasal 
bone presence 93.98% 31.82% p < 0.001
NT — nuchal translucency; MoM — multiples of the median
Table 5. The assessment of nasal bone presence
All 
patients
Present nasal 
bone
Absent nasal 
bone
The number of 
examined patients 6661 6431 95.54% 230 3.43%
Healthy fetuses 6617 6417 96.98% 200 3.02%
Trisomy 18 and 
13 fetuses 44 14 31.82% 30 68.18%
Table 4. Assessment of DR and FPR depending on the cut-off point 
for Trisomy 18 and 13
DR FPR
NT +
PAPP-A
NT + NB +
PAPP-A
NT +
PAPP-A
NT + NB +
PAPP-A
1:300 84.1% 93.2% 7.1% 5.6%
1:200 81.8% 90.9% 4.5% 3.8%
1:100 68.2% 81.8% 2.2% 2.2%
1:50 56.8% 75.0% 1.1% 1.1%
DR — detection rate; FPR — fetal heart rate; NB — nasal bone; NT — nuchal 
translucency
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In every the assessed groups according to risk (> 1:300, 
> 1:200, > 1:100, > 1:50) an increase in the study’s correctness 
and a decrease in FPR after including the nasal bone screen-
ing was obtained: for groups at risk > 1:300 DR increased 
from 84% to 93% with a decrease in FPR from 7.1% to 5.6%; 
and for the group at risk > 1:50 DR increased from 56% to 
75% at the FPR level of 1.1% for both groups (Tab. 4).
The risk of Trisomy 18 and 13 is in relation to maternal 
age, CRL, nuchal translucency scan and fetal heart rates, as 
well as a double test. In our studies, we additionally evalu-
ated the presence or absence of the nasal bone. Thanks to 
the evaluation of the nasal bone, we have obtained both 
an increase in the sensitivity of the examination as well as 
a decrease in FPR (Chart 1, 2).
Nuchal translucency was above 95th percentile in 4.9% 
of cases in the control group. In fetuses with Trisomy 18 in 
81% and in fetuses with Trisomy 13 in 91% of cases. (Tab. 6).
In the group in which the nasal bone was not assessed, 
but only the nuchal translucency and the double test (con-
trol group) were evaluated, the area under the curve in the 
ROC analysis was 0.8434. On the contrary, the area under 
the curve in the group with nasal bone assessment (study 
group) in the ROC analysis was 0.9539. The absence of a nasal 
bone is a very good marker of Trisomy 18 and 13 because 
the area under the curve in ROC analysis when the screening 
nasal bone assessment is included increased from 0.8434 to 
0.9593 (Fig. 1, 2).
DISCUSSION
The most frequent human chromosomes are Down syn-
drome (Trisomy 21) — 1 case for 800 live births, Edwards 
Syndrome (Trisomy 18 — 1 case for 3,500 to 8,000 live births) 
and Patau Syndrome (Trisomy 13) — 1 case out of 6,500 live 
births [5, 6]. Most fetuses with genetic abnormalities die 
intrauterine at various stages of development, and the in-
cidence of genetic is estimated to be significantly higher 
[6]. The risk of Edwards and Patau Syndrome depends on 
the age of the mother and increases with it [7]. However, 
about 80% of fetuses with genetic abnormalities occur in 
women under 35 years of age [8]. According to Kroes [1], 
69% of mothers whose fetuses had a Trisomy were under 
35 years old.
Screening tests used to assess the risk of Trisomy of 21, 
18 and 13 are performed between 11+0 and 13+6 weeks of 
gestation. The detection of Trisomy 21, 18 and 13 depends 
on the test method, i.e. the number of ultrasound markers 
evaluated, and biochemical tests performed. The basic ul-
trasound marker for chromosomal aberration assessment 
is nuchal translucency and fetal heart rate (FHR) [7]. Nuchal 
translucency above the 95th percentile occurs in approxi-
mately 72% of Down Syndrome cases [8], while in Edwards 
and Patau Syndrome only in 66% and 44% of cases assessed 
in prenatal tests during the first trimester of pregnancy re-
spectively [9]. In our study, nuchal translucency above the 
95th percentile occurred in 81% of Edwards’ Syndrome and 
91% of Patau Syndrome.
Detection (DR) of Trisomy 18 and 13 in screening tests in 
the first trimester of pregnancy, i.e. based on basal markers 
(maternal age, NT, fetal heart rate and assessing the double 
test) is approximately 87% at FPR 5.3% [4]. According to 
Kagan et al. [13], when examining mother’s age, nuchal 
Table 6. Nuchal Translucency above 95th percentile in study group
Control 
group
Edward’s 
Syndrome
Patau 
Syndrome
NT percentage above 95th 
percentile 4.9% 81% 91%
NT — nuchal translucency
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Figure 1. ROC curve for Trisomy 18 and 13 prediction using risk 
18 and 13 in the group in which the patient’s age, NT FHR and 
PAPP-A test were assessed
Figure 2. ROC curve for Trisomy prediction 18 and 13 using risk 
18 and 13 in the group in which the patient’s age, NT, FHR, NB and 
PAPP-A test were assessed
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translucency and performing a biochemical test (double 
test), the detection of Trisomy 18 and 13 is 97% and 94% 
respectively at FPR 3.1%. In our studies, assessing maternal 
age, nuchal translucency, fetal heart function and perform-
ing a double test at 4.5% FPR a detection rate (DR) of 81% 
for Trisomy 18 and 13 was obtained (Tab. 4).
The nasal bone is an additional ultrasound indicator as-
sessed in screening tests in the first trimester of pregnancy 
to assess the risk of Trisomy 21, 18 and 13 [11–13]. The nasal 
bone does not occur in approximately 0.1–2.8% of healthy 
fetuses [14]. Absence of the nasal bone in healthy fetuses 
depends on the mother’s ethnicity [12]: most often it does 
not occur in African-Americans (10.4%), less often in Asians 
(6.8%), while the most rarely absence of the nasal bone is 
found in Caucasians (2.8%) [15]. In our material, no nasal 
bone in 3.02% of healthy foetuses was found. The nasal 
bone is more often absent in the Trisomy 21 than in Trisomy 
18 and 13 [12, 14]. In Edwards’ Syndrome, the nasal bone is 
absent in about 52–80% of cases [15, 16], while in Patau’s 
Syndrome in about 31–67% of cases [8, 12, 15]. Our results 
show similar values — in 68% of fetuses with Trisomy 18 and 
13 we did not find the presence of nasal bone.
In our study, after including the nasal bone assess-
ment into the screening, the sensitivity of the examina-
tion in each case was increased by about 10–20% (DR for 
risk > 1: 300 from 84.1% to 93.2%, for risk > 1: 200 from 
81.8% to 90.9%, for risk > 1: 100 from 68.2% to 81.8%, and 
for risk > 1:50 from 56.8% to 75%) . At the same time the false 
positive results were reduced FPR from 7.1% at cut-off point 
for risk > 1: 300 to 1.1% at cut-off point for risk > 1:50 (Tab. 4).
After including the presence or absence of the nasal 
bone assessment into the screening Kagan et al. [13] did not 
observe in their studies changes in the detection of Trisomy 
18 and 13 — at a cut-off point for 1:100 the detection of 
Trisomy 18 and 13 remained on this level (DR for Trisomy 
18:92%; DR for Trisomy 13:83%) with an FPR of 2.5%. In our 
study, for a cut-off point of > 1:100 taking into account the 
assessment of the nasal bone compared to the test without 
assessment of the nasal bone, the sensitivity increased from 
68% to 81%, with the same level of FPR — 2.2% .
We stated that the absence of a nasal bone was a very 
accurate additional marker of Trisomy 18 and 13. The area 
under the curve in the ROC analysis is statistically important 
and noticeable (p < 0.0001). After including the nasal bone 
screening an increase in DR was obtained with a decrease 
in FPR. Therefore, we believe that the assessment of the risk 
of Trisomy 18 and 13 should be carried out not only in scope 
of mother’s age, fetal heart rate and nuchal translucency 
thickness but also using an additional ultrasound marker 
which is the presence or absence of the nasal bone. For this 
reason, we agree with other authors [17] that nasal bone 
assessment is a good marker of Trisomy 18 and 13, but we 
disagree that it should not be considered in the trisomy risk 
assessment algorithm.
CONCLUSIONS
Concluding, it should be noted that the qualitative anal-
ysis of the assessment of the nasal bone in the first trimester 
significantly influences the improvement of screening val-
ues focusing on Trisomy 18 and 13 detection. In summary, 
our research indicates a more effective type of Trisomy 13 
and 18 screening using NT, double test, maternal age, 
CRL and FHR as well as nasal bone presence and absence.
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